Noxafil Tablet, Coated
Product Images NDC 0085-4324

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Noxafil (NDC 0085-4324). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Noxafil 01)

Figure 1 (Noxafil 01)
FDA Label Image

Chemical Structure (Noxafil 02)

Chemical Structure (Noxafil 02)
FDA Label Image

Figure A (Noxafil 02a)

Figure A (Noxafil 02a)
FDA Label Image

Principal Display Panel (105 mL Bottle Carton)

Principal Display Panel (105 mL Bottle Carton)
NOXAFIL is an oral suspension medication that comes in a package of 105 mL. Each 5 mL contains 200mg of posaconazole. The medication comes with a measuring spoon for an accurate dosage. It is essential to note that NOXAFIL oral suspension and delayed-release tablets cannot be interchanged due to the difference in dosing. It is recommended to store the medication at 77°F and to shake the medication before consuming it.*
FDA Label Image

Principal Display Panel (60 Tablet Bottle Label)

Principal Display Panel (60 Tablet Bottle Label)
Noxafl is a prescription medication that comes in a delayed-release tablet form containing 100mg of posaconazole. The medication is not interchangeable with Noxafl Oral Suspension due to differences in dosing. The tablets should be stored at room temperature between 68-77°F and 59-86°F. The product has a National Drug Code (NDC) of 0085-4324-02 and a GTIN of 00300854324025. The package contains 60 tablets.*
FDA Label Image

Principal Display Panel (16.7 mL Vial Carton)

Principal Display Panel (16.7 mL Vial Carton)
Noxafil is an injectable medication containing 300mg posaconazole per 16.7 mL via, intended for intravenous use only. Inactive ingredients include 668 betadex suffobutyl ether sodium, 00033g edetate disodium, and hycochloric acid and sodium hydroxide to adjust the pH. The medication is manufactured for Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc. and manufactured by MSD International GmbH in Ireland. Noxafil is a clear, sterile solution that requires further dilution prior to infusion. The usual dosage information can be found in the accompanying directions, and any remaining solution should be stored in the refrigerator for up to 24 hours. The product is a sterile single-dose vial and requires a prescription.*
FDA Label Image

Figure (Noxafil 06)

Figure (Noxafil 06)
FDA Label Image

Figure (Noxafil 07)

Figure (Noxafil 07)
FDA Label Image

Figure (Noxafil 08)

Figure (Noxafil 08)
FDA Label Image

Figure (Noxafil 09)

Figure (Noxafil 09)
FDA Label Image

Figure (Noxafil 10)

Figure (Noxafil 10)
FDA Label Image

Figure (Noxafil 11)

Figure (Noxafil 11)
FDA Label Image

Figure (Noxafil 12)

Figure (Noxafil 12)
FDA Label Image

Figure (Noxafil 13)

Figure (Noxafil 13)
FDA Label Image

Figure (Noxafil 14)

Figure (Noxafil 14)
FDA Label Image

Figure (Noxafil 15)

Figure (Noxafil 15)
FDA Label Image

Figure (Noxafil 16)

Figure (Noxafil 16)
FDA Label Image

Figure (Noxafil 17)

Figure (Noxafil 17)
FDA Label Image

Figure (Noxafil 18)

Figure (Noxafil 18)
FDA Label Image

Figure (Noxafil 19)

Figure (Noxafil 19)
FDA Label Image

Figure (Noxafil 20)

Figure (Noxafil 20)
FDA Label Image

Figure (Noxafil 21)

Figure (Noxafil 21)
FDA Label Image

Figure (Noxafil 22)

Figure (Noxafil 22)
FDA Label Image

Figure (Noxafil 23)

Figure (Noxafil 23)
FDA Label Image

Figure (Noxafil 24)

Figure (Noxafil 24)
FDA Label Image

Figure (Noxafil 25)

Figure (Noxafil 25)
FDA Label Image

Figure (Noxafil 26)

Figure (Noxafil 26)
FDA Label Image

Figure (Noxafil 27)

Figure (Noxafil 27)
FDA Label Image

Figure (Noxafil 28)

Figure (Noxafil 28)
FDA Label Image

Figure (Noxafil 29)

Figure (Noxafil 29)
FDA Label Image

Figure (Noxafil 30)

Figure (Noxafil 30)
FDA Label Image

Figure (Noxafil 31)

Figure (Noxafil 31)
FDA Label Image

Figure (Noxafil 32)

Figure (Noxafil 32)
FDA Label Image

Figure (Noxafil 33)

Figure (Noxafil 33)
FDA Label Image

Figure (Noxafil 34)

Figure (Noxafil 34)
FDA Label Image

Figure (Noxafil 35)

Figure (Noxafil 35)
FDA Label Image

Figure (Noxafil 36)

Figure (Noxafil 36)
FDA Label Image

Figure (Noxafil 37)

Figure (Noxafil 37)
FDA Label Image

Figure (Noxafil 38)

Figure (Noxafil 38)
FDA Label Image

Figure (Noxafil 39)

Figure (Noxafil 39)
FDA Label Image

Figure (Noxafil 40)

Figure (Noxafil 40)
FDA Label Image

Figure (Noxafil 41)

Figure (Noxafil 41)
FDA Label Image

Figure (Noxafil 42)

Figure (Noxafil 42)
FDA Label Image

Principal Display Panel (300 mg Carton)

Principal Display Panel (300 mg Carton)
Noxafil PowderMix is an oral suspension containing 300mg of posaconazole. It is stored at a room temperature of 20 to 25°C and should be administered with the provided notched-tip syringes within an hour of mixing. The recommended dosage and usage instructions can be found in the prescribing information provided. The Multi-Dose Kit contains instructions for use, syringes, mixing liquid, bottle adapter, and 8 packets of Noxafil PowderMix. Additional notched-tip syringes are provided in Package B.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.